Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
蓋利艾德股價正在上漲，因公司宣佈了第三階段試驗的中期結果，顯示每年兩次使用Lenacapavir將HIV感染率降低了96%。
Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
吉利德公司公佈了3期試驗的中期業績，顯示每年兩次的來那卡韋將艾滋病毒感染率降低了96％，此後，吉利德股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。